Clinical Trial Update: TYK2 Inhibition in Paradoxical Psoriasis [Phase 2, Phase 3]

View source ↗

Summary

Terminated Phase 2/Phase 3 trial evaluating a TYK2 inhibitor for psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Snippet

Sponsor: Prof Curdin Conrad | Conditions: Psoriasis | Phase 2, Phase 3 | Status: TERMINATED